Log In
Print
BCIQ
Print
Print this Print this
 

PINTA 745 (formerly AMG 745)

  Manage Alerts
Collapse Summary General Information
Company Atara Biotherapeutics Inc.
DescriptionRecombinant Fc-peptide fusion protein
Molecular Target Myostatin (GDF8) (MSTN)
Mechanism of ActionMyostatin (GDF-8) inhibitor
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationEnd-stage renal disease (ESRD)
Indication DetailsTreat patients with end-stage renal disease (ESRD) who are on hemodialysis and have protein energy wasting (PEW)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today